Etoposide 50mg Cap
| Product Overview | |
| Generic Name | Etoposide 50mg Cap |
| Brand Name(s) | Vepesid®, Floposid®, Etopophos® |
| Form | Oral Capsule |
| Strength | 50 mg |
| Therapeutic Class | Topoisomerase II inhibitor |
| ATC Code | L01CB01 |
| Manufacturing & Regulatory | |
| Manufacturer | Ocean Pharmaceutical, AdvaCare, Florencia, Aetos, Revetus, Lexicare |
| Country | India |
| GMP Compliance | WHO-GMP certified facility |
| DMF/CEP | Unknown – request from mfg |
| COFEPRIS | Registered – exact Clave pending |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 x 100 Cap, packs |
| Shelf Life | 24-36 Months |
| Storage | room temp for capsules |
| Incoterms | Exworks, DDP, FOB |
| Lead Time | 7 to 10 days |
| Documentation | |
| Certificate of Analysis (COA) | Manufacturer provides COA |
| SDS | Available on request |
| CTD Summary | Available upon purchase with fee |
Description
Indications & Usage: Etoposide is a semisynthetic podophyllotoxin derivative that inhibits topoisomerase II. Used in SCLC, testicular, bladder, lymphoma, leukemia, neuroblastoma, and as conditioning for stem cell transplant. Administered IV or orally. Common toxicities: myelosuppression, alopecia, GI issues. It's on the WHO essential medicines list. Used in lung (SCLC), testicular, lymphoma; monitor myelosuppression
